Literature DB >> 17426658

Elastolytic matrix metalloproteinases and coronary outcome in children with Kawasaki disease.

Andrew C Lau1, Hans Rosenberg, Trang T Duong, Brian W McCrindle, Rae S M Yeung.   

Abstract

Kawasaki disease (KD) is a multisystem vasculitis that leads to coronary artery damage and aneurysm formation. Elastolytic matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of arterial aneurysms. To determine the relationship between circulating levels of elastolytic MMPs and development of coronary artery aneurysms in children with KD, we partnered studies done in affected children with an animal model of disease. In affected children, circulating protein levels and enzymatic activity of MMP-2 and MMP-9 did not have a statistically significant relationship with coronary artery outcome after adjusting for demographic characteristics, and clinical and laboratory features. Although matrix-degrading proteolytic activity was specific for affected mice and localized to inflamed coronary artery segments, the enzymatic activity in the systemic circulation of affected and control mice were not different. Similar to affected children, peripheral blood levels of MMP-9 enzymatic activity did not correlate with coronary artery disease in the animal model. Therefore, circulating levels of MMPs known to act locally may not be useful biomarkers of disease. This is especially relevant to enzymatic activity that is tightly regulated at multiple levels including the local tissue environment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426658     DOI: 10.1203/pdr.0b013e318053418b

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Study design and rationale to assess Doxycycline Efficacy in preventing coronary Artery Lesions in children with Kawasaki disease (DEAL trial) - A phase II clinical trial.

Authors:  Andras Bratincsak; Blair N Limm-Chan; Vivek R Nerurkar; Lauren L Ching; Venu D Reddy; Eunjung Lim; Ralph V Shohet; Marian E Melish
Journal:  Contemp Clin Trials       Date:  2017-12-05       Impact factor: 2.226

2.  The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.

Authors:  S Blankier; B W McCrindle; S Ito; R S M Yeung
Journal:  Clin Exp Immunol       Date:  2011-03-01       Impact factor: 4.330

Review 3.  Comparative effectiveness of intravenous immunoglobulin from different manufacturing processes on Kawasaki disease.

Authors:  Ming-Chih Lin
Journal:  World J Pediatr       Date:  2014-05-07       Impact factor: 2.764

4.  Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease.

Authors:  A C Lau; T T Duong; S Ito; G J Wilson; R S M Yeung
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

5.  Plasma matrix metalloproteinases in neonates having surgery for congenital heart disease.

Authors:  Ari R Joffe; Christina Schulz; Rhonda J Rosychuk; John Dyck; Ivan M Rebeyka; David B Ross; Richard Schulz; Po-Yin Cheung
Journal:  Heart Int       Date:  2009-06-30

6.  Salvianolic Acid B Down-regulates Matrix Metalloproteinase-9 Activity and Expression in Tumor Necrosis Factor-α-induced Human Coronary Artery Endothelial Cells.

Authors:  Le Ma; Yun-Qian Guan; Zhong-Dong Du
Journal:  Chin Med J (Engl)       Date:  2015-10-05       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.